Roche, Isis ally to develop Huntington's disease drugs

04/9/2013 | Yahoo

Roche Holding and Isis Pharmaceuticals agreed to collaborate in the development of Huntington's disease drugs using the latter's antisense technology. The partners will initially focus on Isis' lead drug candidate designed to inhibit production of all forms of a protein involved in the genetic brain disorder. Isis will get $30 million upfront and as much as $362 million in licensing and milestone fees plus sales royalties on drugs arising from the collaboration.

View Full Article in:

Yahoo

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Vice President of Regulatory Affairs
Pentec Health
Boothwyn, PA
Sr Coordinator Clinical Research (US/TA/00/0073/SL) - 1400000AQX
Abbott
Santa Clara, CA
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA